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From perpetual haemosiderinuria to possible iron overload:
iron redistribution in paroxysmal nocturnal haemoglobinuria
patients on eculizumab by magnetic resonance imaging
Paroxysmal nocturnal haemoglobinuria (PNH) was initially
named ‘chronic haemolytic anaemia with perpetual haemosid-
erinuria’, and often results in iron deficiency secondary to
urinary iron loss (Parker et al, 2005). Eculizumab is an
inhibitor of complement component 5, which has been
shown effective in the control of complement-mediated
intravascular haemolysis of PNH (Hillmen et al, 2006; Kelly
et al, 2011; Risitano et al, 2011). We investigated iron com-
partmentalization in 20 haemolytic PNH patients: two
untreated, 14 on eculizumab, and four analysed before and
during eculizumab treatment (Table I). Standard biochemical
testing, including iron parameters and flow cytometry for
complement component 3 (C3) on erythrocytes, was com-
bined with magnetic resonance imaging (MRI) to assess cal-
culated iron content (CIC) of kidneys, liver and spleen
(Gandon et al, 1994; Deugnier & Turlin, 2007).
The six patients not (yet) treated with eculizumab had
overt intravascular haemolysis (high lactate dehydrogenase
(LDH) levels and haemosiderinuria) and normal/low serum
ferritin levels (Table I). Regardless of transfusion require-
ment, all of them showed a homogeneous pattern of iron
compartmentalization (Mathieu et al, 1995), characterized by
renal cortex siderosis (renal CIC > 200) and absence of hep-
ato-splenic iron deposition (liver and spleen CIC were nor-
mal) (Fig. 1A). In contrast, three distinct patterns of iron
tissue deposition were identified in the PNH patients receiv-
ing eculizumab (Table I; Fig. 1E): (i) Low iron levels in liver,
spleen and kidneys, (n = 5; Fig. 1B); (ii) high iron levels in
liver and/or spleen and low in kidneys (n = 9; Fig. 1C); (iii)
high iron levels in liver, spleen and kidney (n = 3). In one of
the treated patients, the iron deposition pattern was similar
to that of untreated patients. All the four patients studied
before and during eculizumab showed resolution or reduc-
tion of renal siderosis, with two of them developing a pro-
gressive liver iron overload.
Looking for possible explanations for distinct patterns of
iron tissue deposition we correlated tissue specific CICs with
measures of iron status (ferritin, transferrin saturation and
haemosiderinuria) and markers of intravascular haemolysis.
Kidney iron content, expressed as CIC, did not correlate with
any parameter but with haemosiderinuria (P < 0·001). Very
high renal CIC levels (>100 units), similar to untreated
patients, were present in only 22% (4 out 18) of patients on
eculizumab: three patients had signs of chronic residual
intravascular haemolysis, whereas one had experienced a
recent breakthrough episode. Liver and spleen CIC directly
correlated each other (P < 0,001, r2 = 0·62) but not with
renal CIC. Both liver and spleen CIC showed a direct corre-
lation with serum ferritin (P < 0·001, r2 = 0·79; P < 0·001,
r2 = 0·81) but not with transferrin saturation, LDH and hae-
mosiderinuria. Fifteen patients showed some degree of liver
iron overload that, remarkably, was not restricted to patients
still requiring blood transfusions: it was mild in 8, moderate
in six and severe only in 1 (Table I). In contrast with the
low/normal serum ferritin levels present in untreated patients
(regardless of transfusion requirement), 10 patients on ecu-
lizumab showed high serum ferritin levels ( 300 lg/l),
which was associated with liver iron overload (mild, moder-
ate and severe in 4, 5 and 1 cases, respectively). Iron tissue
content was studied by liver biopsy in two patients: severe
hepatocellular iron overload was found in the transfusion-
dependent patient RM003 (high ferritinaemia and transferrin
saturation) but not in the transfusion independent patient
NA003 (moderate increase of ferritinaemia and normal trans-
ferrin saturation).
To unravel the mechanisms underlying iron overload in
PNH patients on eculizumab, we correlated liver CIC with
haematological parameters during anti-complement therapy
and response to treatment. Liver CIC did not correlate with
the duration of eculizumab treatment or with others biomar-
kers of response (including LDH) with the exception of the
inverse correlation with haemoglobin levels (P = 0·02,
r2 = 0·28). Accordingly, patients with suboptimal response
(Hb < 110 g/l; Risitano et al, 2009a) had higher liver CIC
than patients with optimal response (P = 0·02). Suboptimal
response has been associated with the development of vari-
able degrees of extravascular haemolysis, which is probably
secondary to C3 opsonization of PNH erythrocytes (Risitano
et al, 2009a, 2011). Indeed, we found that liver CIC corre-
lated directly with the absolute reticulocyte count (ARC;
P = 0·02, r2 = 0·26), which is an index of residual haemoly-
sis, and with the percentage of C3-opsonized PNH erythro-
cytes (P = 0·01, r2 = 0·31), which has been previously
identified as a surrogate marker of extravascular haemolysis
in PNH patients on eculizumab (Risitano et al, 2009a).
Increased ferritin has been described recently as a possible
finding in PNH patients on eculizumab (Risitano et al,
2009b; Ro¨th et al, 2011); here we demonstrate that such
ª 2012 Blackwell Publishing Ltd, British Journal of Haematology doi:10.1111/j.1365-2141.2012.09145.x
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hyperferritinaemia reflects iron redistribution occurring dur-
ing eculizumab treatment, possibly resulting in tissue iron
overload. Indeed, when complement-mediated intravascular
haemolysis is adequately blocked by eculizumab, the abolish-
ment of perpetual haemosiderinuria results in normalization
of renal siderosis. On the other hand, the blockade of urinary
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Fig 1. Iron compartmentalization by magnetic resonance imaging (MRI) in PNH patients. After informed consent, T2* MRI was performed by a
1·5 tesla whole body scanner (Gyroscan, Philips, Andover, MA, USA), using four gradient-echo sequences and one spin-echo sequence. Due to
paramagnetic properties of iron, iron overload results in decreased T2* relaxation time at MRI. This gives a typical image of the involved organ,
with decreased (black) signal intensity (SI) corresponding to iron overload, while organs with normal iron content appear white. SI was measured
on images obtained with each sequence by means of three regions of interest placed in the liver and at the level of the para-spinal muscle. SI
ratios were obtained in comparison to muscle, and finally converted into organ calculated iron content (CIC) according to the validated method
described by Gandon et al (1994). CIC of the liver was expressed as lmol/g (Gandon et al, 1994; Deugnier & Turlin, 2007), whereas for the kid-
neys and the spleen CICs were reported as arbitrary units because the formal validation on tissue biopsies has never been performed for ethical
and medical reasons. (A) Example of an untreated PNH patient (UPN NA111): MR image demonstrates a high renal CIC (dashed white arrows)
and normal hepatosplenic CIC (white arrows). (B) Example of a PNH patient on eculizumab experiencing breakthrough (UPN NA102): MR
image demonstrates a high renal CIC (dashed white arrows) and normal hepatosplenic CIC (white arrows), similarly to untreated patients. (C)
Example of a PNH patient on eculizumab with complete blockade of intravascular haemolysis (UPN NA006): MR image demonstrates normal
CIC in the kidneys (dashed white arrows), liver and spleen (white arrows). (D) Example of a PNH patient on eculizumab with iron overload
(UPN RM003): MR image demonstrates a normal renal CIC (dashed white arrows) and high hepatic CIC (white arrow). (E) Calculated iron con-
tent in kidneys, liver and spleen as determined by MRI: organ specific CIC were obtained using the same formula (Gandon et al, 1994), but are
expressed as either lmol/g of tissue (liver) or arbitrary units (kidneys and spleen). Each dot represents a single case, with the exception of those
tagged as 1 and 2, which refer to the same patient studied at 1 and 6 months from treatment initiation; pre- and post-treatment data (when
available) are joined by a continuous line. The dotted line represents the normal range for liver CIC.
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iron loss eventually renders PNH patients susceptible to the
accumulation of iron in the liver and spleen, possibly devel-
oping meaningful iron overload. In patients who remain
transfusion-dependent, tissue iron overload is probably dri-
ven by positive net iron balance, whereas in transfusion-inde-
pendent patients it may be secondary to the C3-mediated
extravascular haemolysis, which is present at some degree in
all eculizumab-treated patients (Risitano et al, 2011). Indeed,
the destruction of C3 + PNH erythrocytes in the liver and
in the spleen generates iron deposition as ferritin within the
macrophage reticulo-endothelial system (seen as hyperferriti-
naemia). Eventually, in some case this iron deposition may
affect hepatocytes and other parenchymas because of the pro-
gressive saturation of reticulo-endothelial system storage
capacity, and/or active iron export into the plasma driven by
suppressed hepcidin levels secondary to the continuous
erythropoietic stress. The histological finding that hepatocel-
lular overload was demonstrated only in the presence of
increased transferrin saturation suggests that a clinically rele-
vant iron overload may develop mainly in presence of a posi-
tive iron balance, whereas increased ferritin should not
necessarily imply organ impairment in most transfusion-free
patients. However, the possible long-term consequences of
iron redistribution during eculizumab treatment and the pos-
sible need of specific therapeutic interventions will have to
be assessed in future clinical studies.
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